ET140203 T Cells for Pediatric Liver Cancers
This study is testing a treatment called ET140203 T Cells for children and young adults (ages 1 to 21) with certain liver cancers: hepatoblastoma (HB), hepatocellular carcinoma (HCC), or hepatic adenoma not otherwise specified (HCN-NOS). These cancers must have returned after standard treatment or not responded to it. The ET140203 T Cells are made from your own immune cells, which are specially modified to fight the cancer. The main goal of this study is to see how safe ET140203 T Cells are and to find the best dose. To join, your cancer must have a specific marker called AFP (alpha-fetoprotein) above 100 ng/mL. The study is currently unclear on its recruitment status and plans to enroll 12 participants.
- Study design
- This is an open-label, multi-center study that will gradually increase the dose of ET140203 T Cells to find the safest and most effective amount. It is a Phase I/II trial, meaning it focuses on safety first, then looks at how well the treatment works.
- What's involved
- You would have tumor assessments, including imaging and blood tests for AFP levels, before the first treatment and then at months 1, 3, 6, 9, 12, 18, and 24. The active part of the study lasts for 2 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- After the initial 2 years of active assessment, participants will be followed for safety and overall survival for an additional 13 years, up to 15 years total.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
At a glance
Conditions
NCT04634357
Where you'd take part
This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Children's Hospital Los Angeles
Los Angeles, Californiastudy coordinator listed
Recruiting
Children's Hospital Orange County
Orange, Californiastudy coordinator listed
Recruiting
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston, Massachusettsstudy coordinator listed
Recruiting
UCSF Benioff Children's Hospitals
San Francisco, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Pei Wang, PhD · STUDY_DIRECTOR · Eureka Therapeutics Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence rates of adverse events (AEs) after infusion of ET140203 T cells28 days
Safety of ET140203 T cells as assessed by the number of adverse events (AEs) after infusion
- Severity rates of adverse events (AEs) after infusion of ET140203 T cells28 days
Safety of ET140203 T cells as assessed by the severity of adverse events (AEs) after infusion.
- Incidence rates of dose limiting toxicities (DLTs) after infusion of ET140203 T cells28 days
Tolerability of ET140203 T cells after infusions assessed by committee review of dose limiting toxicities (DLTs)
- The recommended phase 2 dose (RP2D) regimen of ET140203 T cell therapy primarily based on DLTUp to 2 years
The RP2D will be determined by the study Dose Escalation Committee (DEC) and primarily based on DLTs.